ArticleBlood advances2026
Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
abstractAn increase in the absolute lymphocyte count (ALC) is a component of progressive disease (PD) in chronic lymphocytic leukemia (CLL) and contributes to progression-free survival in phase 3 trials. Prior studies with chemoimmunotherapy demonstrated that PD by ALC alone (ALC PD) conferred better outcomes than other modalities of PD (other PD). To evaluate the incidence and impact of ALC PD with modern treatments, we retrospectively examined 339 consecutive patients with CLL/small lymphocytic lymphoma treated between 2016 and 2025 at the University of Washington/Fred Hutchinson Cancer Center. Patients received frontline therapy with continuous Bruton tyrosine kinase inhibitors (BTKi; n = 179), bendamustine-rituximab (BR; n = 66), and time-limited B-cell lymphoma 2 inhibitors (BCL2i; n = 94). The cumulative incidence of ALC PD was higher with BR than BTKi and BCL2i (P = .021). Across treatment groups, overall survival (OS) from progression was longer for ALC PD than other PD (median, 116 vs 71 months; P = .0012; hazard ratio [HR], 3.15; 95% confidence interval [CI], 1.52-6.53), with 5-year OS rates of 83% and 56%, respectively. Time to next treatment or death (TTNT-D) was longer for ALC PD (median, 14 vs 2.2 months; P< .0001). OS from treatment initiation was longest for nonprogressors, intermediate for ALC PD (HR, 3.62; 95% CI, 1.48-8.85), and worst for other PD (HR, 11.7; 95% CI, 5.99-22.9). These findings suggest that ALC PD may vary based on treatment modality and is associated with longer survival and TTNT-D. If confirmed in larger phase 3 data sets, future response criteria may consider reporting ALC PD separately from other PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.